The global Ofatumumab market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
This report is a detailed and comprehensive analysis for global Ofatumumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ofatumumab market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Ofatumumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Ofatumumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Ofatumumab market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (US$/Kg), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ofatumumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ofatumumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BOC Sciences, GlaxoSmithKline(GSK), Lonza Group, Novartis International, TargetMol Chemicals, Hubei Kele Fine Chemical, Jiangxi Ruiweier Biotechnology, Nantong Feiyu Biological Technology, Shanghai Biochempartner, Shanghai Macklin Biochemical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Ofatumumab market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Patent
Generic
麻豆原创 segment by Application
Chemical
Pharmaceutical
Major players covered
BOC Sciences
GlaxoSmithKline(GSK)
Lonza Group
Novartis International
TargetMol Chemicals
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Nantong Feiyu Biological Technology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Yifei Biotechnology
Tianmen Hengchang Chemical
Wuhan Topule Biopharmaceutical
Wuhan Wogeda Biotechnology
Wuhan Yingnuo Pharmaceutical Technology
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ofatumumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ofatumumab, with price, sales quantity, revenue, and global market share of Ofatumumab from 2020 to 2025.
Chapter 3, the Ofatumumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ofatumumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Ofatumumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ofatumumab.
Chapter 14 and 15, to describe Ofatumumab sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Ofatumumab Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Patent
1.3.3 Generic
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Ofatumumab Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Chemical
1.4.3 Pharmaceutical
1.5 Global Ofatumumab 麻豆原创 Size & Forecast
1.5.1 Global Ofatumumab Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Ofatumumab Sales Quantity (2020-2031)
1.5.3 Global Ofatumumab Average Price (2020-2031)
2 Manufacturers Profiles
2.1 BOC Sciences
2.1.1 BOC Sciences Details
2.1.2 BOC Sciences Major Business
2.1.3 BOC Sciences Ofatumumab Product and Services
2.1.4 BOC Sciences Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 BOC Sciences Recent Developments/Updates
2.2 GlaxoSmithKline(GSK)
2.2.1 GlaxoSmithKline(GSK) Details
2.2.2 GlaxoSmithKline(GSK) Major Business
2.2.3 GlaxoSmithKline(GSK) Ofatumumab Product and Services
2.2.4 GlaxoSmithKline(GSK) Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 GlaxoSmithKline(GSK) Recent Developments/Updates
2.3 Lonza Group
2.3.1 Lonza Group Details
2.3.2 Lonza Group Major Business
2.3.3 Lonza Group Ofatumumab Product and Services
2.3.4 Lonza Group Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Lonza Group Recent Developments/Updates
2.4 Novartis International
2.4.1 Novartis International Details
2.4.2 Novartis International Major Business
2.4.3 Novartis International Ofatumumab Product and Services
2.4.4 Novartis International Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Novartis International Recent Developments/Updates
2.5 TargetMol Chemicals
2.5.1 TargetMol Chemicals Details
2.5.2 TargetMol Chemicals Major Business
2.5.3 TargetMol Chemicals Ofatumumab Product and Services
2.5.4 TargetMol Chemicals Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 TargetMol Chemicals Recent Developments/Updates
2.6 Hubei Kele Fine Chemical
2.6.1 Hubei Kele Fine Chemical Details
2.6.2 Hubei Kele Fine Chemical Major Business
2.6.3 Hubei Kele Fine Chemical Ofatumumab Product and Services
2.6.4 Hubei Kele Fine Chemical Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Hubei Kele Fine Chemical Recent Developments/Updates
2.7 Jiangxi Ruiweier Biotechnology
2.7.1 Jiangxi Ruiweier Biotechnology Details
2.7.2 Jiangxi Ruiweier Biotechnology Major Business
2.7.3 Jiangxi Ruiweier Biotechnology Ofatumumab Product and Services
2.7.4 Jiangxi Ruiweier Biotechnology Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Jiangxi Ruiweier Biotechnology Recent Developments/Updates
2.8 Nantong Feiyu Biological Technology
2.8.1 Nantong Feiyu Biological Technology Details
2.8.2 Nantong Feiyu Biological Technology Major Business
2.8.3 Nantong Feiyu Biological Technology Ofatumumab Product and Services
2.8.4 Nantong Feiyu Biological Technology Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Nantong Feiyu Biological Technology Recent Developments/Updates
2.9 Shanghai Biochempartner
2.9.1 Shanghai Biochempartner Details
2.9.2 Shanghai Biochempartner Major Business
2.9.3 Shanghai Biochempartner Ofatumumab Product and Services
2.9.4 Shanghai Biochempartner Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Shanghai Biochempartner Recent Developments/Updates
2.10 Shanghai Macklin Biochemical
2.10.1 Shanghai Macklin Biochemical Details
2.10.2 Shanghai Macklin Biochemical Major Business
2.10.3 Shanghai Macklin Biochemical Ofatumumab Product and Services
2.10.4 Shanghai Macklin Biochemical Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Shanghai Macklin Biochemical Recent Developments/Updates
2.11 Shanghai Yifei Biotechnology
2.11.1 Shanghai Yifei Biotechnology Details
2.11.2 Shanghai Yifei Biotechnology Major Business
2.11.3 Shanghai Yifei Biotechnology Ofatumumab Product and Services
2.11.4 Shanghai Yifei Biotechnology Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Shanghai Yifei Biotechnology Recent Developments/Updates
2.12 Tianmen Hengchang Chemical
2.12.1 Tianmen Hengchang Chemical Details
2.12.2 Tianmen Hengchang Chemical Major Business
2.12.3 Tianmen Hengchang Chemical Ofatumumab Product and Services
2.12.4 Tianmen Hengchang Chemical Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Tianmen Hengchang Chemical Recent Developments/Updates
2.13 Wuhan Topule Biopharmaceutical
2.13.1 Wuhan Topule Biopharmaceutical Details
2.13.2 Wuhan Topule Biopharmaceutical Major Business
2.13.3 Wuhan Topule Biopharmaceutical Ofatumumab Product and Services
2.13.4 Wuhan Topule Biopharmaceutical Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Wuhan Topule Biopharmaceutical Recent Developments/Updates
2.14 Wuhan Wogeda Biotechnology
2.14.1 Wuhan Wogeda Biotechnology Details
2.14.2 Wuhan Wogeda Biotechnology Major Business
2.14.3 Wuhan Wogeda Biotechnology Ofatumumab Product and Services
2.14.4 Wuhan Wogeda Biotechnology Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Wuhan Wogeda Biotechnology Recent Developments/Updates
2.15 Wuhan Yingnuo Pharmaceutical Technology
2.15.1 Wuhan Yingnuo Pharmaceutical Technology Details
2.15.2 Wuhan Yingnuo Pharmaceutical Technology Major Business
2.15.3 Wuhan Yingnuo Pharmaceutical Technology Ofatumumab Product and Services
2.15.4 Wuhan Yingnuo Pharmaceutical Technology Ofatumumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Wuhan Yingnuo Pharmaceutical Technology Recent Developments/Updates
3 Competitive Environment: Ofatumumab by Manufacturer
3.1 Global Ofatumumab Sales Quantity by Manufacturer (2020-2025)
3.2 Global Ofatumumab Revenue by Manufacturer (2020-2025)
3.3 Global Ofatumumab Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Ofatumumab by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Ofatumumab Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Ofatumumab Manufacturer 麻豆原创 Share in 2024
3.5 Ofatumumab 麻豆原创: Overall Company Footprint Analysis
3.5.1 Ofatumumab 麻豆原创: Region Footprint
3.5.2 Ofatumumab 麻豆原创: Company Product Type Footprint
3.5.3 Ofatumumab 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Ofatumumab 麻豆原创 Size by Region
4.1.1 Global Ofatumumab Sales Quantity by Region (2020-2031)
4.1.2 Global Ofatumumab Consumption Value by Region (2020-2031)
4.1.3 Global Ofatumumab Average Price by Region (2020-2031)
4.2 North America Ofatumumab Consumption Value (2020-2031)
4.3 Europe Ofatumumab Consumption Value (2020-2031)
4.4 Asia-Pacific Ofatumumab Consumption Value (2020-2031)
4.5 South America Ofatumumab Consumption Value (2020-2031)
4.6 Middle East & Africa Ofatumumab Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Ofatumumab Sales Quantity by Type (2020-2031)
5.2 Global Ofatumumab Consumption Value by Type (2020-2031)
5.3 Global Ofatumumab Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Ofatumumab Sales Quantity by Application (2020-2031)
6.2 Global Ofatumumab Consumption Value by Application (2020-2031)
6.3 Global Ofatumumab Average Price by Application (2020-2031)
7 North America
7.1 North America Ofatumumab Sales Quantity by Type (2020-2031)
7.2 North America Ofatumumab Sales Quantity by Application (2020-2031)
7.3 North America Ofatumumab 麻豆原创 Size by Country
7.3.1 North America Ofatumumab Sales Quantity by Country (2020-2031)
7.3.2 North America Ofatumumab Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Ofatumumab Sales Quantity by Type (2020-2031)
8.2 Europe Ofatumumab Sales Quantity by Application (2020-2031)
8.3 Europe Ofatumumab 麻豆原创 Size by Country
8.3.1 Europe Ofatumumab Sales Quantity by Country (2020-2031)
8.3.2 Europe Ofatumumab Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Ofatumumab Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Ofatumumab Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Ofatumumab 麻豆原创 Size by Region
9.3.1 Asia-Pacific Ofatumumab Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Ofatumumab Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Ofatumumab Sales Quantity by Type (2020-2031)
10.2 South America Ofatumumab Sales Quantity by Application (2020-2031)
10.3 South America Ofatumumab 麻豆原创 Size by Country
10.3.1 South America Ofatumumab Sales Quantity by Country (2020-2031)
10.3.2 South America Ofatumumab Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Ofatumumab Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Ofatumumab Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Ofatumumab 麻豆原创 Size by Country
11.3.1 Middle East & Africa Ofatumumab Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Ofatumumab Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Ofatumumab 麻豆原创 Drivers
12.2 Ofatumumab 麻豆原创 Restraints
12.3 Ofatumumab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Ofatumumab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Ofatumumab
13.3 Ofatumumab Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Ofatumumab Typical Distributors
14.3 Ofatumumab Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
BOC Sciences
GlaxoSmithKline(GSK)
Lonza Group
Novartis International
TargetMol Chemicals
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Nantong Feiyu Biological Technology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Yifei Biotechnology
Tianmen Hengchang Chemical
Wuhan Topule Biopharmaceutical
Wuhan Wogeda Biotechnology
Wuhan Yingnuo Pharmaceutical Technology
听
听
*If Applicable.
